RCM
THRD

RA Capital Management’s Third Harmonic Bio THRD Stock Holding History

RA Capital Management’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-960,620
Closed -$9.88M – 97
2024
Q4 		$9.88M Sell
960,620
-320,206
-25% -$3.99M 0.13% 73
2024
Q3 		$17.4M Sell
1,280,826
-752,230
-37% -$9.32M 0.2% 57
2024
Q2 		$26.4M Hold
2,033,056
– – 0.35% 46
2024
Q1 		$19.2M Hold
2,033,056
– – 0.24% 60
2023
Q4 		$22.3M Buy
2,033,056
+1,071,193
+111% +$8.49M 0.35% 46
2023
Q3 		$6.15M Buy
+961,863
New +$5.88M 0.12% 61
2023
Q1 		– Sell
-534,687
Closed -$2.3M – 68
2022
Q4 		$2.3M Sell
534,687
-2,941,000
-85% -$49.2M 0.05% 64
2022
Q3 		$65.9M Buy
+3,475,687
New +$62.6M 1.41% 22

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RA Capital Management's THRD Position: Q1 2025 in Review

RA Capital Management sold out of Third Harmonic Bio (THRD) in Q1 2025, closing a stake of 960,620 shares — an estimated $9.88M sold.

RA Capital Management first reported a position in THRD in Q3 2022 and held it in 8 quarters. The position peaked at $65.9M in Q3 2022. 100 funds tracked by Wall St. Rank hold THRD as of Q1 2025.

  • RA Capital Management reported no remaining Third Harmonic Bio position as of Q1 2025 after selling out during the quarter.
  • RA Capital Management sold 960,620 Third Harmonic Bio shares in Q1 2025, an estimated $9.88M.
  • RA Capital Management first reported a position in Third Harmonic Bio in Q3 2022 and held it in 8 quarters.
  • RA Capital Management's Third Harmonic Bio position peaked at $65.9M in Q3 2022.
  • 100 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q1 2025.

Based on RA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.